RESTRUCTURING AND INTEGRATION COSTS	6 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND INTEGRATION COSTS	RESTRUCTURING AND INTEGRATION COSTS On April 1, 2015, the Company acquired Salix Pharmaceuticals, Ltd. (“Salix”), pursuant to an Agreement and Plan of Merger dated February 20, 2015, as amended on March 16, 2015 (the “Salix Merger Agreement”), with Salix surviving as a wholly owned subsidiary of Valeant Pharmaceuticals International (“Valeant”), a subsidiary of the Company (the “Salix Acquisition”). In connection with the Salix Acquisition and other acquisitions, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings. These measures included: (i) workforce reductions company-wide and other organizational changes, (ii) closing of duplicative facilities and other site rationalization actions company-wide, including research and development facilities, sales offices and corporate facilities, (iii) leveraging research and development spend and (iv) procurement savings. Salix Acquisition-Related Cost-Rationalization and Integration Initiatives Cost-rationalization and integration initiatives relating to the Salix Acquisition were substantially completed by mid-2016. Total costs incurred primarily include: employee termination costs payable to approximately 475 employees of the Company and Salix who have been terminated as a result of the Salix Acquisition; costs to consolidate or close facilities and relocate employees; and contract termination and lease cancellation costs. Since the acquisition date, total costs of $273 million have been incurred through June 30, 2017, including: (i) $153 million of integration expenses, (ii) $105 million of restructuring expenses and (iii) $15 million of acquisition-related costs. Salix Integration Costs Salix integration costs were $0 and $15 million, and payments were $1 million and $19 million for the six months ended June 30, 2017 and 2016, respectively. The remaining liability associated with these activities as of June 30, 2017 was $6 million. Salix Restructuring Costs Salix restructuring costs incurred were $6 million and $8 million, and payments were $4 million and $23 million for the six months ended June 30, 2017 and 2016, respectively. The remaining liability associated with these activities as of June 30, 2017 was $11 million. Other Restructuring and Integration-Related Costs (Excluding Salix) During the six months ended June 30, 2017, in addition to the Salix restructuring and integration costs, the Company incurred $30 million of other restructuring and integration-related costs. These costs included: (i) $15 million of integration consulting, transition service, and other costs, (ii) $8 million of facility closure costs and (iii) $7 million of severance costs. The Company made payments of $44 million for the six months ended June 30, 2017 (in addition to the payments related to Salix). The remaining liability associated with these activities as of June 30, 2017 was $40 million. During the six months ended June 30, 2016, in addition to the Salix restructuring and integration costs, the Company incurred $35 million of other restructuring and integration-related costs. These costs included: (i) $25 million of integration consulting, duplicate labor, transition service, and other costs, (ii) $6 million of severance costs and (iii) $4 million of facility closure costs. These costs primarily related to restructuring and integration costs for other smaller acquisitions. The Company made payments of $39 million for the six months ended June 30, 2016 (in addition to the payments related to Salix). The Company continues to evaluate opportunities to improve its operating results and may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs could be material and may include, but are not limited to, expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.

RESTRUCTURING AND INTEGRATION COSTS

On April 1, 2015, the Company acquired Salix Pharmaceuticals, Ltd. (“Salix”), pursuant to an Agreement and Plan of Merger dated February 20, 2015, as amended on March 16, 2015 (the “Salix Merger Agreement”), with Salix surviving as a wholly owned subsidiary of Valeant Pharmaceuticals International (“Valeant”), a subsidiary of the Company (the “Salix Acquisition”).

In connection with the Salix Acquisition and other acquisitions, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings. These measures included: (i) workforce reductions company-wide and other organizational changes, (ii) closing of duplicative facilities and other site rationalization actions company-wide, including research and development facilities, sales offices and corporate facilities, (iii) leveraging research and development spend and (iv) procurement savings.

Salix Acquisition-Related Cost-Rationalization and Integration Initiatives

Cost-rationalization and integration initiatives relating to the Salix Acquisition were substantially completed by mid-2016. Total costs incurred primarily include: employee termination costs payable to approximately 475 employees of the Company and Salix who have been terminated as a result of the Salix Acquisition; costs to consolidate or close facilities and relocate employees; and contract termination and lease cancellation costs. Since the acquisition date, total costs of $273 million have been incurred through June 30, 2017, including: (i) $153 million of integration expenses, (ii) $105 million of restructuring expenses and (iii) $15 million of acquisition-related costs.

Salix Integration Costs

Salix integration costs were $0 and $15 million, and payments were $1 million and $19 million for the six months ended June 30, 2017 and 2016, respectively. The remaining liability associated with these activities as of June 30, 2017 was $6 million.

Salix Restructuring Costs

Salix restructuring costs incurred were $6 million and $8 million, and payments were $4 million and $23 million for the six months ended June 30, 2017 and 2016, respectively. The remaining liability associated with these activities as of June 30, 2017 was $11 million.

Other Restructuring and Integration-Related Costs (Excluding Salix)

During the six months ended June 30, 2017, in addition to the Salix restructuring and integration costs, the Company incurred $30 million of other restructuring and integration-related costs. These costs included: (i) $15 million of integration consulting, transition service, and other costs, (ii) $8 million of facility closure costs and (iii) $7 million of severance costs. The Company made payments of $44 million for the six months ended June 30, 2017 (in addition to the payments related to Salix). The remaining liability associated with these activities as of June 30, 2017 was $40 million.

During the six months ended June 30, 2016, in addition to the Salix restructuring and integration costs, the Company incurred $35 million of other restructuring and integration-related costs. These costs included: (i) $25 million of integration consulting, duplicate labor, transition service, and other costs, (ii) $6 million of severance costs and (iii) $4 million of facility closure costs. These costs primarily related to restructuring and integration costs for other smaller acquisitions. The Company made payments of $39 million for the six months ended June 30, 2016 (in addition to the payments related to Salix).

The Company continues to evaluate opportunities to improve its operating results and may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses. The expenses associated with the implementation of these cost savings programs could be material and may include, but are not limited to, expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.